Robin A L
Glaucoma Services, Sinai Hospital of Baltimore, MD.
Arch Ophthalmol. 1988 Jul;106(7):912-5. doi: 10.1001/archopht.1988.01060140058024.
A prospective, double-masked, randomized study evaluated the effects of unilateral therapy with topical 1% apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145) in 20 normal volunteers. No medications were applied to either eye during the control day. Following baseline measurements on the day of treatment, one drop of topical 1% apraclonidine hydrochloride was placed on one eye and a placebo (vehicle) was placed on the fellow eye. Intraocular pressure (IOP) measurements, pupil size, blood pressure, and pulse rate were assessed on both days at the baseline and 1, 3, 5, and 7 hours later. The 1% apraclonidine hydrochloride lowered the mean IOP (+/- SD) a maximum of 6.5 +/- 4.3 mm Hg (37.3% +/- 20.4%) from the baseline on the day of treatment. A statistically significant 2.7 +/- 3.4-mm Hg (14.9% +/- 19.0%) mean IOP decrease from the baseline was noted in the contralateral placebo-treated eye. No significant changes in the coefficient of outflow, blood pressure, or heart rate were noted. Eyelid retraction, conjunctival blanching, and mydriasis were frequently noted in eyes treated with 1% apraclonidine hydrochloride.
一项前瞻性、双盲、随机研究评估了局部使用1%盐酸阿可乐定（盐酸阿可乐定或ALO 2145）进行单侧治疗对20名正常志愿者的影响。在对照日，两只眼睛均未使用任何药物。在治疗当天进行基线测量后，将一滴局部用1%盐酸阿可乐定滴入一只眼睛，另一只眼睛滴入安慰剂（赋形剂）。在基线以及治疗后1、3、5和7小时，对两天的眼压（IOP）测量值、瞳孔大小、血压和脉搏率进行评估。1%盐酸阿可乐定在治疗当天使平均眼压（±标准差）从基线水平最多降低了6.5±4.3毫米汞柱（37.3%±20.4%）。在对侧接受安慰剂治疗的眼睛中，观察到平均眼压从基线水平有统计学意义的降低，为2.7±3.4毫米汞柱（14.9%±19.0%）。未观察到流出系数、血压或心率有显著变化。在接受1%盐酸阿可乐定治疗的眼睛中，经常观察到眼睑退缩、结膜苍白和瞳孔散大。
